AMO Pharma Announces Update on Scientific Advice for Registrational Clinical Study of AMO-02 in Congenital Myotonic Dystrophy Type 1 Following Meetings with the U.S. Food and Drug Administration, the U.K. Medicines and Healthcare products Regulatory Agency and Health Canada
Based on regulatory agency feedback, the Company plans a registrational study that will evaluate hospitalization as the primary outcome measure, supported by multiple functional assessments as secondary outcome measures. LONDON, July 6, 2026 /PRNewswire/ -- AMO Pharma Limited ("AMO...
Based on regulatory agency feedback, the Company plans a registrational study that will evaluate hospitalization as the primary outcome measure, supported by multiple functional assessments as secondary outcome measures. LONDON, July 6, 2026 /PRNewswire/ -- AMO Pharma Limited ("AMO...
Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.